切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2020, Vol. 08 ›› Issue (02) : 113 -117. doi: 10.3877/cma.j.issn.2095-5820.2020.02.009

所属专题: 文献

质量控制

六西格玛在肿瘤标志物质量目标选择上的应用
杨伏猛1, 刘倩1,(), 张子龄1, 陈丽1, 滕士阶1, 梁伟1   
  1. 1. 222006 江苏连云港,连云港市第二人民医院检验科
  • 收稿日期:2019-08-07 出版日期:2020-05-28
  • 通信作者: 刘倩
  • 基金资助:
    江苏省连云港市卫生科研计划项目(201817); 南京医科大学康达学院科研发展基金重点项目(KD2019KYJJZD010)

Application of Six Sigma in the selection of quality objectives of tumor markers

Fumeng Yang1, Qian Liu1,(), Ziling Zhang1, Li Chen1, Shijie Teng1, Wei Liang1   

  1. 1. Department of Laboratory, The Second People’s Hospital of Lianyungang, Lianyungang Jiangsu 222006, China
  • Received:2019-08-07 Published:2020-05-28
  • Corresponding author: Qian Liu
  • About author:
    Corresponding author: Liu Qian, Email:
引用本文:

杨伏猛, 刘倩, 张子龄, 陈丽, 滕士阶, 梁伟. 六西格玛在肿瘤标志物质量目标选择上的应用[J/OL]. 中华临床实验室管理电子杂志, 2020, 08(02): 113-117.

Fumeng Yang, Qian Liu, Ziling Zhang, Li Chen, Shijie Teng, Wei Liang. Application of Six Sigma in the selection of quality objectives of tumor markers[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2020, 08(02): 113-117.

目的

应用6σ理论对肿瘤标志物项目的分析性能进行评价,并初步确定各项目的质量目标。

方法

收集本实验室2018年1至12月室内质控数据和国家卫生健康委临床检验中心室间质量评价结果,以生物学变异导出的质量规范和国家室间质量评价标准作为允许总误差(TEa)计算6项肿瘤标志物的σ水平,并依据质量目标选择流程图和肿瘤标志物分析性能验证图评价肿瘤标志物的分析性能,进而为肿瘤标志物选择合适的质量目标。

结果

应用不同层级的生物学变异导出的质量规范和国家室间质量评价标准,肿瘤标志物项目的σ水平存在显著差异;依据质量目标选择流程图:选择生物学变异导出的"适当的"质量规范作为CA125项目的质量目标,选择生物学变异导出的"最低的"质量规范作为t-PSA、CEA、AFP、CA199和CA153项目的质量目标。

结论

6σ能够客观评价肿瘤标志物的分析性能,并为实验室质量目标的选择提供重要的参考价值。

Objective

Six Sigma theory was applied to evaluate the analytical performance of tumor markers, and the quality objectives of each project were preliminarily determined.

Methods

The internal quality control (IQC) data and external quality assessment (EQA) of National Center for Clinical Laboratories in our laboratory from January to December 2018 were collected, and the quality specification derived from biological variation and the standard of EQA were used as allowable total error (TEa) to calculate Sigma levels of six tumor markers. According to the flow chart of quality goal selection and the validation chart for analytical performance of tumor markers, the analytical performance of each project were evaluated, and then the appropriate quality objectives of tumor markers were determined.

Results

There were significant differences among sigma levels of tumor markers by applying the quality specification derived from different levels of biological variation and the standard of EQA. According to the quality objectives, choose flow chart "appropriate" quality criteria derived from biological variation as CA125 quality objectives, and "minimal" quality criteria derived from biological variation as t-PSA, CEA, AFP, CA199 and CA153 quality objectives.

Conclusion

Six Sigma can objectively evaluate the analytical performance of tumor markers and provide an important guidance for the selection of laboratory quality objectives.

表1 不同质量目标时的肿瘤标志物项目的σ水平
图1 质量目标选择流程图
图2 肿瘤标志物分析性能验证图("适当的"生物学变异)
图3 肿瘤标志物分析性能验证图("最低的"生物学变异)
表2 不同质量目标时项目分析性能的分布情况(%)
1
Fraser CG. The 1999 Stockholm Consensus Conference on quality specifications in laboratory medicine[J]. Clin Chem Lab Med, 2015, 53(6):837-840.
2
Sandberg S, Fraser CG, Horvath AR, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine[J]. Clin Chem Lab Med, 2015, 53(6):833-835.
3
Panteghini M, Sandberg S. Total error vs. measurement uncertainty: the match continues[J]. Clin Chem Lab Med, 2016, 54(2):195-196.
4
Hollestelle MJ, Ruinemans-Koerts J, Idema RN, et al. Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice?[J]. Clin Chem Lab Med, 2019, 57(8):1235-1241.
5
Taher J, Cosme J, Renley BA, et al. A novel Sigma metric encompasses global multi-site performance of 18 assays on the Abbott Alinity system[J]. Clin Biochem, 2019,63:106-112.
6
Liu Q, Fu M, Yang F, et al. Application of Six Sigma for evaluating the analytical quality of tumor marker assays[J]. J Clin Lab Anal, 2019, 33(2):22682.
7
Varela B, Pacheco G. Comprehensive evaluation of the internal and external quality control to redefine analytical quality goals[J]. Biochem Med (Zagreb), 2018, 28(2):20710.
8
何赏, 陈琛, 王成彬. 精准医疗、精准检验、检验精准[J]. 中华检验医学杂志, 2017, 40(4):221-223.
9
Dainis AM, Ashley EA. Cardiovascular Precision Medicine in the Genomics Era[J]. JACC Basic Transl Sci. 2018, 3(2):313-326.
10
李润青, 宫丽君, 王腾蛟, 等. 西格玛方法在临床生化检验质量管理中的应用[J]. 中华检验医学杂志, 2017, 40(9):727-732.
11
张诗诗, 王薇, 赵海建, 等. 常规临床检验项目如何选择不同分析性能规范模型[J]. 临床检验杂志, 2017, 35(2):89-93.
12
Sten W, Hassan B, Westgard JO. Analytical Sigma metrics: A review of Six Sigma implementation tools for medical laboratories[J]. Biochem Med (Zagreb), 2018, 28(2):20502.
13
Guo X, Zhang T, Gao X, et al. Sigma metrics for assessing the analytical quality of clinical chemistry assays: a comparison of two approaches: Electronic supplementary material available online for this article[J]. Biochem Med (Zagreb), 2018, 28(2):20708.
14
Hens K, Berth M, Armbruster D, et al. Sigma metrics used to assess analytical quality of clinical chemistry assays: importance of the allowable total error (TEa) target[J]. Clin Chem Lab Med, 2014, 52(7):973-980.
15
章晓燕, 王薇, 赵海建, 等. 生物学变异推导出的质量规范在肿瘤标志物检测指标质量评价中的应用[J]. 临床检验杂志, 2016, 34(5):388-391.
16
El Sharkawy R, Westgard S, Awad AM, et al. Comparison between Sigma metrics in four accredited Egyptian medicallaboratories in some biochemical tests: an initiative towards sigma calculation harmonization[J]. Biochem Med (Zagreb), 2018, 28(2):20711.
[1] 陈海涛, 章敬尧, 朱冰, 管佳佳, 傅军. 血清循环DNA在胃癌中的诊断及预后的价值[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 18-22.
[2] 杨立胜, 刘梦鸾, 任维聃, 姜国胜, 刘桂伟. 基于血清肿瘤标志物预测结直肠癌肝转移模型价值分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 39-43.
[3] 闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J/OL]. 中华普通外科学文献(电子版), 2023, 17(05): 391-394.
[4] 陈晓曼, 张海波, 薛曼婕, 魏波, 邵军, 韩晓燕. -80℃低温保藏对结直肠癌血浆miRNA标志物的影响[J/OL]. 中华普通外科学文献(电子版), 2023, 17(01): 24-27.
[5] 谢汶歆, 马乐, 刘晔, 曹晓明, 张万春. 前列腺特异性膜抗原PET/CT在肾癌诊疗中的应用价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 514-519.
[6] 谭智勇, 付什, 李宁, 王海峰, 王剑松. 膀胱小细胞癌发病机制及其诊疗研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 183-187.
[7] 张琳, 吴波, 王东文. 前列腺癌特异性近红外荧光探针的研究进展与展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 6-11.
[8] 王震, 宋艳敏, 王琛, 王福平. 甲磺酸奥西替尼用于中晚期肺癌患者对肿瘤标志物及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2022, 15(06): 826-828.
[9] 李新雄, 张再重, 赵虎, 肖春红, 王烈. 作为胰腺癌生物标志物的外泌体内容物研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(01): 53-57.
[10] 丁成明, 侯嘉丰, 陶光伟, 齐硕, 谢翼, 冯灿, 陈振坤, 蒋心渺, 邓鑫, 彭健. 肝细胞癌早期诊断和筛查[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(01): 22-28.
[11] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[12] 万菲, 任勇军. 原发性肝细胞癌肿瘤标志物研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 77-81.
[13] 莫婧, 陈国伟, 张世玉. 术后不同时间腹腔热灌注化疗对卵巢癌患者肿瘤标志物水平的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(02): 165-170.
[14] 陶莹, 李晓光, 朱桃红, 杨彦, 陈琦. Westgard西格玛规则在中孕期母血清学产前筛查质量管理中的应用[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(02): 65-69.
[15] 裴世静, 万艳红, 刘金萍, 高奇, 马斌国. 山西省全血细胞计数室间质量评价不同分析性能规范的应用探讨[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(01): 16-21.
阅读次数
全文


摘要